Drug Trial Radar · NCT04683003
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
Last checked: Nov 19, 2026Latest source record: Apr 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
77
Planned (sponsor's estimate)
Start
Apr 14, 2021
Primary completion
Mar 16, 2027
Study completion Mar 16, 2027
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- Collaborators
- Takeda Development Center Americas, Inc.; Shire
- First posted
- Dec 24, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 0 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Thrombotic thrombocytopenic purpura (or TTP for short) is a condition where blood clots form in small blood vessels throughout the body. The clots can limit or block the flow of oxygen-rich blood to the body's organs, such as the brain, kidneys, and heart. As a result, serious health problems can develop. The increased clotting that occurs in TTP uses up the cells that help the blood to clot, called platelets. With fewer platelets available in the blood, bleeding problems can also occur. People who have TTP may bleed underneath the skin forming purple bruises, or purpura. TTP also can cause anemia, a condition in which red blood cells break apart faster than the body can replace them, leading to fewer red blood cells than in normal. TTP is caused by a lack of activity in the ADAMTS13 enzyme, a protein in the blood involved in controlling clotting of the blood. The ADAMTS13 enzyme breaks up another blood protein called von Willebrand factor that forms blood clots by clumping together with platelets. Some people are born with this condition, while others develop the condition during their life. Many people who are born with TTP experience frequent flare-ups that need to be treated right away. TAK-755 is a medicine that replaces ADAMTS13 and may prevent or control TTP flare-ups, called acute TTP events. The main aim of the study is to check for side effects of long-term treatment with TAK-755. Treatment will be given in 2 ways: 1. TAK-755 treatment given either every week or every other week to prevent acute TTP events from happening (the "prophylactic" cohort). 2. TAK-755 treatment given to control an acute TTP event when it happens (the "on-demand" cohort). Participants in the prophylactic cohort will receive treatment in the clinic or at home for up to approximately 3 years. They will visit the clinic at least every 12 weeks. Participants in the on-demand cohort will receive daily treatment for the acute TTP event until the flare-up has gotten better. They will have a follow-up visit at the clinic 4 weeks later.
Conditions
- Thrombotic Thrombocytopenic Purpura (TTP)
Interventions
TAK-755Biological
TAK-755 IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Related Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)Time frame: Throughout the study period of approximately 6 years
Locations
27 sites in 11 countries. Site status is shown where the registry gives one.
Childrens Healthcare of Atlanta
Atlanta, Georgia
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Duke University Medical Center
Durham, North Carolina
Mid Ohio Heart Clinic Inc
Dublin, Ohio
University of Oklahoma
Oklahoma City, Oklahoma
AKH - Medizinische Universität Wien
Vienna, Austria
Beijing Children's Hospital
Beijing, Beijing Municipality, China
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China
Tongji Hospital Affiliated to Tongji Medicine University
Wuhan, Hubei, China
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsushe, China
Institute of Hematology and Hospital of Blood Disease
Tianjin, Tianjin Municipality, China
Hôpital Saint-Antoine
Paris, France
Hôpital Robert Debré- Paris
Paris, France
Hôpital Necker - Enfants Malades
Paris, Paris, France
CHU Saint Etienne - Hôpital Nord
Saint-Priest-en-Jarez Cedex, Pays de la Loire Region, France
Universitaetsklinikum Hamburg-Eppendorf
Hamburg, Germany
Universitaetsklinikum Jena, Klinik fuerKinder-und Jugendmedizin
Jena, Germany
Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)
Bergamo, Hubei, Italy
Kyushu University Hospital
Fukuoka, Fukuoka, Japan
Hyogo College of Medicine Hospital
Nishinomiya, Hyōgo, Japan
Medical Hospital,Tokyo Medical and Dental University
Bunkyo City, Tokyo, Japan
Samodzielny Publiczny Dzieciecy Szpital Kliniczny
Warsaw, Poland
Instytut Hematologii i Transfuzjologii
Warsaw, Poland
Complejo Hospitalario Universitario A Coruña
A Coruña, La Coruña, Spain
Hospital de Cruces
Barakaldo, Vizcaya, Spain
Inselspital -Universitaetsspital Bern
Bern, Switzerland
University College London Hospitals
London, Greater London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.